Fabry disease has two faces: a classic childhood form, and a later-onset cardiac form that is far more common, yet mostly undiagnosed.

Fabry disease is an X-linked lysosomal storage disorder caused by GLA mutations that reduce or abolish alpha-galactosidase A activity, letting globotriaosylceramide build up in the vascular endothelium, kidney, heart and nervous system. Classic Fabry, with near-absent enzyme activity, presents in childhood with neuropathic pain, angiokeratoma and reduced sweating, progressing over decades to renal failure, hypertrophic cardiomyopathy and stroke. US prevalence of diagnosed classic Fabry is estimated at 5,000 to 10,000 patients, about 1 in 40,000 males, but that figure counts only the recognised population.

The larger, quieter story is the later-onset phenotype. Patients with residual enzyme activity often present in their fifties or sixties with isolated cardiac or kidney disease and are frequently missed. Long-term registry data show the leading cause of death shifting from renal failure toward cardiac disease as kidney management has improved. Because Fabry is X-linked, female heterozygotes are not merely carriers; many develop significant multi-organ disease, typically about a decade later than males. Layered on top is the treatment split: roughly 35% to 50% of patients carry a GLA mutation amenable to the oral chaperone migalastat, and the rest depend on intravenous enzyme replacement.

The undiagnosed later-onset cardiac pool may outsize the classic Fabry population.

Five questions this report answers:

Q1 - How large is the undiagnosed later-onset Fabry pool in the US?

Q2 - How does the Fabry organ timeline unfold from childhood pain to organ failure?

Q3 - How does GLA-mutation amenability split patients into oral-chaperone versus ERT-only groups?

Q4 - How common is diagnosed classic Fabry disease among US males?

Q5 - Why has cardiac disease overtaken renal failure as Fabry's leading cause of death?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#FabryDisease #LysosomalStorageDisorder #RareDisease #Nephrology #Cardiology #USHealthcare

Live report page:  https://axlrx.ai/fabry-disease/disease-landscape/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-           hello@axlrx.ai

Web-           https://axlrx.ai/